Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24

British Journal of Dermatology

Volumn 167, Issue 1, 2012, Pages 92-102

  Wang, Frank ^a   Smith, N ^a   Maier, L ^a   Xia, W ^a   Hammerberg, C ^a   Chubb, H ^a   Chen, C ^a   Riblett, M ^a   Johnston, A ^a   Gudjonsson, J E ^a   Helfrich, Y ^a   Kang, S ^b   Fisher, G J ^a   Voorhees, J J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; BETA DEFENSIN 2; BETA DEFENSIN 3; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CXCL1 CHEMOKINE; CYTOKERATIN 16; CYTOKERATIN 17; ETANERCEPT; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12P40; INTERLEUKIN 17; INTERLEUKIN 19; INTERLEUKIN 1BETA; INTERLEUKIN 20; INTERLEUKIN 22; INTERLEUKIN 23P19; INTERLEUKIN 24; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ABSENCE OF SIDE EFFECTS; ARTICLE; CELL STIMULATION; CLINICAL TRIAL; DOWN REGULATION; DRUG EFFECT; EPIDERMIS; EPIDERMIS HYPERPLASIA; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOGENESIS; IN VITRO STUDY; KERATINOCYTE; PRIORITY JOURNAL; PSORIASIS; T LYMPHOCYTE ACTIVATION; TARGET CELL; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DENDRITIC CELLS; DOWN-REGULATION; EPIDERMIS; HUMANS; HYPERPLASIA; IMMUNOGLOBULIN G; INTERLEUKINS; KERATINOCYTES; LYMPHOCYTE ACTIVATION; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; REGENERATION; T-LYMPHOCYTES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84863300416     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.10961.x     Document Type: Article

References (47)

1. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007; 445:866-73.
2. Clark RA. Skin-resident T cells: the ups and downs of on site immunity. J Invest Dermatol 2010; 130:362-70.
3. Johnson-Huang LM, McNutt NS, Krueger JG et al. Cytokine-producing dendritic cells in the pathogenesis of inflammatory skin diseases. J Clin Immunol 2009; 29:247-56.
4. Zaba LC, Krueger JG, Lowes MA. Resident and 'inflammatory' dendritic cells in human skin. J Invest Dermatol 2009; 129:302-8.
5. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009; 361: 496-509.
6. Ciric B, El-Behi M, Cabrera R et al. IL-23 drives pathogenic IL-17-producing CD8+ T cells. J Immunol 2009; 182:5296-305.
7. Duhen T, Geiger R, Jarrossay D et al. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009; 10:857-63.
8. Sonnenberg GF, Fouser LA, Artis D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol 2011; 12:383-90.
9. Liang SC, Tan XY, Luxenberg DP et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006; 203: 2271-9. (Pubitemid 44498362)
10. Nograles KE, Zaba LC, Guttman-Yassky E et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008; 159:1092-102.
11. Harper EG, Guo C, Rizzo H et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol 2009; 129:2175-83.
12. Wolk K, Kunz S, Witte E et al. IL-22 increases the innate immunity of tissues. Immunity 2004; 21:241-54. (Pubitemid 39094053)
13. Boniface K, Bernard FX, Garcia M et al. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 2005; 174:3695-702. (Pubitemid 40354080)
14. Zheng Y, Danilenko DM, Valdez P et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 445:648-51. (Pubitemid 46232884)
15. Sa SM, Valdez PA, Wu J et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 2007; 178:2229-40. (Pubitemid 46233421)
16. Res PC, Piskin G, de Boer OJ et al. Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS ONE 2010; 5:e14108.
17. Romer J, Hasselager E, Norby PL et al. Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine A or calcipotriol. J Invest Dermatol 2003; 121:1306-11. (Pubitemid 38005477)
18. Wang F, Lee E, Lowes MA et al. Prominent production of IL-20 by CD68+/CD11c+ myeloid-derived cells in psoriasis: gene regulation and cellular effects. J Invest Dermatol 2006; 126:1590-9.
19. Kunz S, Wolk K, Witte E et al. Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs. Exp Dermatol 2006; 15:991-1004. (Pubitemid 44688369)
20. Tohyama M, Hanakawa Y, Shirakata Y et al. IL-17 and IL-22 mediate IL-20 subfamily cytokine production in cultured keratinocytes via increased IL-22 receptor expression. Eur J Immunol 2009; 39:2779-88.
21. Nagalakshmi ML, Murphy E, McClanahan T et al. Expression patterns of IL-10 ligand and receptor gene families provide leads for biological characterization. Int Immunopharmacol 2004; 4:577-92. (Pubitemid 38553881)
22. Wolk K, Kunz S, Asadullah K et al. Cutting edge: immune cells as sources and targets of the IL-10 family members? J Immunol 2002; 168:5397-402. (Pubitemid 34556115)
23. Wolk K, Witte K, Witte E et al. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol 2008; 83:1181-93.
24. Zaba LC, Cardinale I, Gilleaudeau P et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007; 204:3183-94.
25. Parrish-Novak J, Xu W, Brender T et al. Interleukins 19, 20, and 24 signal through two distinct receptor complexes. Differences in receptor-ligand interactions mediate unique biological functions. J Biol Chem 2002; 277:47517-23. (Pubitemid 36159270)
26. Wolk K, Haugen HS, Xu W et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med 2009; 87:523-36.
27. Stoler A, Kopan R, Duvic M et al. Use of monospecific antisera and cRNA probes to localize the major changes in keratin expression during normal and abnormal epidermal differentiation. J Cell Biol 1988; 107:427-46.
28. Mansbridge JN, Knapp AM, Strefling AM. Evidence for an alternative pathway of keratinocyte maturation in psoriasis from an antigen found in psoriatic but not normal epidermis. J Invest Dermatol 1984; 83:296-301. (Pubitemid 14002170)
29. Zaba LC, Suárez-Fariñas M, Fuentes-Duculan J et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 2009; 124:1022-10.
30. Kang S, Cho S, Chung JH et al. Inflammation and extracellular matrix degradation mediated by activated transcription factors nuclear factor-kappaB and activator protein-1 in inflammatory acne lesions in vivo. Am J Pathol 2005; 166:1691-9. (Pubitemid 40734392)
31. Quan T, Qin Z, Xia W et al. Matrix-degrading metalloproteinases in photoaging. J Investig Dermatol Symp Proc 2009; 14:20-4.
32. Elder JT, Fisher GJ, Zhang QY et al. Retinoic acid receptor gene expression in human skin. J Invest Dermatol 1991; 96:425-33.
33. Moore A, Gordon KB, Kang S et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol 2007; 56:598-603. (Pubitemid 46400183)
34. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol 2004; 51:563-9. (Pubitemid 39278075)
35. Otkjaer K, Kragballe K, Funding AT et al. The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis. Br J Dermatol 2005; 153:911-18. (Pubitemid 41540754)
36. Blumberg H, Conklin D, Xu WF et al. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 2001; 104:9-19. (Pubitemid 32144968)
37. Dumoutier L, Leemans C, Lejeune D et al. Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J Immunol 2001; 167:3545-9. (Pubitemid 32910793)
38. Baker BS, Swain AF, Fry L et al. Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br J Dermatol 1984; 110:555-64. (Pubitemid 14146263)
39. Bos JD, Hulsebosch HJ, Krieg SR et al. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res 1983; 275:181-9. (Pubitemid 13056614)
40. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46:1-23. (Pubitemid 34073472)
41. Bhagavathula N, Nerusu KC, Fisher GJ et al. Amphiregulin and epidermal hyperplasia: amphiregulin is required to maintain the psoriatic phenotype of human skin grafts on severe combined immunodeficient mice. Am J Pathol 2005; 166:1009-16. (Pubitemid 40524426)
42. Piepkorn M, Predd H, Underwood R et al. Proliferation-differentiation relationships in the expression of heparin-binding epidermal growth factor-related factors and erbB receptors by normal and psoriatic human keratinocytes. Arch Dermatol Res 2003; 295:93-101. (Pubitemid 36960537)
43. Chiricozzi A, Guttman-Yassky E, Suárez-Fariñas M et al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011; 131:677-87.
44. Haider AS, Cohen J, Fei J et al. Insights into gene modulation by therapeutic TNF and IFNgamma antibodies: TNF regulates IFNgamma production by T cells and TNF-regulated genes linked to psoriasis transcriptome. J Invest Dermatol 2008; 128:655-66. (Pubitemid 351252666)
45. Lee E, Trepicchio WL, Oestreicher JL et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004; 199:125-30. (Pubitemid 38076484)
46. Guilloteau K, Paris I, Pedretti N et al. Skin inflammation induced by the synergistic action of IL-17A, IL-22, oncostatin M, IL-1α, and TNF-α recapitulates some features of psoriasis. J Immunol 2010; 184:5263-70.
47. Schroder JM, Harder J. Human beta-defensin-2. Int J Biochem Cell Biol 1999; 31:645-51. (Pubitemid 29248873)